

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicant: LEBERER, Ekkehard Attorney Docket No.: 38005-0126
Appl. No.: 09/758,036 Confirmation No.: 8288
Filing Date: January 11, 2001 Examiner: Not yet assigned
Art Unit: 1645
Title: Potassium Channel Mutants of the Yeast *Saccharomyces Cerevisiae* and their use for Screening Eukaryotic Potassium Channels

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56 and 37 CFR §1.97**

Director of Patents
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO/SB/08A is a listing of documents known to applicants in order to comply with applicants' duty of disclosure pursuant to 37 C.F.R. §1.56 and §1.97. A copy of each of the listed documents are being submitted to comply with the provisions of 37 C.F.R. §1.97-1.99. A complete copy of references A28 and A42 were unavailable at the time of filing this Information Disclosure Statement. The applicant will submit a copy of these references in due course.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against the claims of the present application.

TIMING/FEE

The instant Information Disclosure Statement is being filed in compliance with 37 CFR §1.97(b) prior to the mailing date of the first official action, therefore, no fee is required in connection with its filing.

Attorney Docket No. 38005-0126

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Respectfully submitted,

Date:

June 11, 2001

By

Patricia D. Granados

HELLER EHRMAN WHITE & MCAULIFFE
1666 K Street, N.W., Suite 300
Washington, DC 20006
Telephone: (202) 912-2777
Facsimile: (202) 912-2020

Patricia D. Granados
Attorney for Applicant
Registration No. 33,683
Customer No. 26633



26633

PATENT TRADEMARK OFFICE

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 4

Complete if Known

| | |
|------------------------|------------------|
| Application Number | 09/758,036 |
| Filing Date | January 11, 2001 |
| First Named Inventor | Ekkehard LEBERER |
| Group Art Unit | 1645 |
| Examiner Name | Unassigned |
| Attorney Docket Number | 38005-0126 |

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|----------|---|----------------|
| | A01 | CURRAN, M.E., et al; "Molecular cloning, characterization, and genomic localization of a human potassium channel gene"; Genomics, 1992; pp. 729-737; Vol. 12; Academic Press, Inc. | |
| | A02 | DASCAL, N. et al; "Atrial G protein-activated K ⁺ channel: Expression cloning and molecular properties"; Proc. Natl. Acad. Sci. USA; November 1993; pp. 10235-10239; Vol. 90; | |
| | A03 | FAIRMAN, C., et al; "Potassium uptake through the TOK1 K ⁺ channel in the budding yeast"; J. Membr. Biol.; 1999; pp. 149-157; Vol. 168; Springer-Verlag New York Inc.; 1999 | |
| | A04 | FEDIDA, D. et al; "The 1997 Stevenson Award Lecture. Cardiac K ⁺ channel gating: cloned delayed rectifier mechanisms and drug modulation" Can. J. Physiol. Pharmacol; 1998; pp 77-89; Vol. 76; NRC Canada; 1998 | |
| | A05 | GABER, R.F. et al; "TRK1 encodes a plasma membrane protein required for high-affinity potassium transport in Saccharomyces cerevisiae" Mol. Cell Biol.; 1988; pp 2848-2859; Vol. 8; American Society for Microbiology; 1988 | |
| | A06 | GOLDSTEIN, S.A. et al; "Three new dominant drug resistant cassettes for gene disruption in Saccharomyces cerevisiae"; Yeast; 1999; pp 1541-1553; Vol. 15; John Wiley & Sons, Ltd. | |
| | A07 | GOLDSTEIN, S.A. et al; "ORK1, a potassium-selective leak channel with two pore domains cloned from Drosophila melanogaster by expression in Saccharomyces cerevisiae"; Proc. Natl. Acad. Sci. USA; November 1996; pp 13256-13261; Vol. 93 | |
| | A08 | GULDENER, U. et al; "A new efficient gene disruption cassette for repeated use in a budding yeast"; Nucleic. Acids. Res; 1996; pp 2519-2524; Vol. 24; Oxford University Press | |
| | A09 | IKEDA, K. et al; "Functional coupling of the nociceptin/orphanin FQ receptor with the G-protein-activated K ⁺ (GIRK) channel"; Brain Res. Mol. Brain Res.; 1997; pp 117-126; Vol. 45; Elsevier Science B.V. | |
| | A10 | ITOH, T. et al; "Genomic organization and mutational analysis of HERG, a gene responsible for familial long QT syndrome"; Hum. Genet.; 1998; pp 435-439; Vol. 102; Springer-Verlag 1998 | |
| | A11 | JAN, L.Y. et al; "Cloned potassium channels from eukaryotes and prokaryotes"; Annu. Rev. Neurosci.; 1997; pp 91-123; Vol. 20; Annual Reviews Inc. | |
| | A12 | JELACIC, T.M. et al; "Functional expression and characterization of G-protein-gated inwardly rectifying K ⁺ channels containing GIRK3" J. Membr. Biol. 1999; pp 123-129; Vol. 169; Springer-Verlag New York Inc.; 1999 | |

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

JUN 14 2001

TECH CENTER 1600/2900



Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Complete if Known

| | |
|------------------------|------------------|
| Application Number | 09/758,036 |
| Filing Date | January 11, 2001 |
| First Named Inventor | Ekkehard LEBERER |
| Group Art Unit | 1645 |
| Examiner Name | Unassigned |
| Attorney Docket Number | 38005-0126 |

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|-----------------------|---|----------------|
| | A13 | KETCHUM, K.A. et al; "A new family of outwardly rectifying potassium channel proteins with two pore domains in tandem"; Nature, August 24, 1995; pp 690-695; Vol. 376 | |
| | A14 | KO, C.H. et al; "TRK2 is required for low affinity K ⁺ Transport in <i>Saccharomyces cerevisiae</i> "; Genetics; June 1990; pp 305-312; Vol. 125; The Genetics Society of America | |
| | A15 | KO, C.H. et al; "TRK1 and TRK2 encode structurally related K ⁺ transporters in <i>Saccharomyces cerevisiae</i> " Mol. Cell. Biol.; 1991; pp 4266-4273; Vol. 11; American Society for Microbiology | |
| | A16 | KUBO, Y. et al; "Primary structure and functional expression of a rat G-protein-coupled muscarinic potassium channel"; Nature, August 26, 1993; pp 802-806; Vol. 364 | |
| | A17 | LUOWIG, A. et al; "Two pacemaker channels from human heart with profoundly different activation kinetics"; EMBO Journal; 1999; pp 2323-2329; Vol. 18 | |
| | A18 | MADRID, R. et al; "Ectopic potassium uptake in trk1 trk2 mutants of <i>Saccharomyces cerevisiae</i> correlates with a highly hyperpolarized membrane potential"; J. Biol. Chem; 1998; pp14838-14844; Vol. 273; The American Society for Biochemistry and Molecular Biology, Inc., United States | |
| | A19 | MAIN, M.J. et al; "The CGRP receptor can couple via pertussis toxin sensitive and insensitive G proteins"; FEBS Lett.; 1998; pp 6-10; Vol. 441; Federation of European Biochemical Societies | |
| | A20 | MUMBERG, D. et al; "Yeast vectors for the controlled expression of heterologous proteins in different genetic backgrounds"; Gene; 1995; pp 119-122; Vol. 156 | |
| | A21 | MYERS, A.M. et al; "Mitochondrial protein synthesis is required for maintenance of intact mitochondrial genomes in <i>Saccharomyces cerevisiae</i> "; EMBO Jour.; 1985; pp 2087-2092; Vol. 4; IRL Press Limited, Oxford England | |
| | A22 | NAKAMURA, R.L. et al; "Determination of key structural requirements of a K ⁺ channel pore"; J. Biol. Chem. 1997; pp 10111-10118; Vol. 272; The American Society for Biochemistry and Molecular Biology, Inc. | |
| | A23 | ROBERDS, S.L. et al; "Cloning and tissue-specific expression of five voltage-gated potassium channel cDNAs expressed in rat heart"; Proc. Natl. Acad. Sci. U.S.A.; 1991; pp 1798-1802; Vol. 88 | |
| | A24 | RONICKE, V. et al; "Use of conditional promoters for expression of heterologous proteins in <i>Saccharomyces cerevisiae</i> "; Methods Enzymol.; 1997; pp 313-322; Vol. 263 | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MKJ/

Copied from 09855340 on 05/06/2005



Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to collect information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 4

Complete if Known

| | |
|------------------------|------------------|
| Application Number | 09/758,036 |
| Filing Date | January 11, 2001 |
| First Named Inventor | Ekkehard LEBERER |
| Group Art Unit | 1645 |
| Examiner Name | Unassigned |
| Attorney Docket Number | 38005-0126 |

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|-----------------------|---|----------------|
| | A25 | SANGUINETTI, M.C. et al; "Molecular physiology of cardiac delayed rectifier K ⁺ channels" Heart Vessels; 1997; pp 170-172; Vol. 12; Springer-Verlag 1997 | |
| | A26 | SCHREIBMAYER, W. et al; "Inhibition of an inwardly rectifying K ⁺ channel by G-protein alpha-subunits"; Nature; 1996; pp 624-627; Vol. 380 | |
| | A27 | SMITH, F.W. et al; "Plant members of a family of sulfate transporters reveal functional subtypes"; Proc. Natl. Acad. Sci. U.S.A.; 1995; pp 9373-9377; Vol. 92 | |
| | A28 | SNYDERS, D.J. et al; "A rapidly activating and slowly inactivating potassium channel cloned from human heart. Functional analysis after stable mammalian cell culture expression"; J. Gen Physiol.; 1993; pp 513-543; Vol. 101 | |
| | A29 | TAGLIALATELA, M. et al; "Human ether-a-gogo related Gene (HERG) K ⁺ channels as pharmacological targets: present and future implications."; Biochem. Pharmacol.; 1999; pp 1741-1748; Vol. 55 | |
| | A30 | TANG, W. et al; "Functional expression of a vertebrate inwardly rectifying K ⁺ channel in yeast"; Mol. Biol. Cell; 1995; pp 1231-1240; Vol. 6; The American Society for Cell Biology | |
| | A31 | WACH, A. et al; "New heterologous modules for classical or PCR-based gene disruptions in Saccharomyces cerevisiae"; Yeast; 1994; pp 1793-1808; Vol. 10; John Wiley & Sons Ltd. | |
| | A32 | WANG, Q. et al; "Genetics, molecular mechanisms and management of long QT syndrome"; Ann. Med.; 1998; pp 58-65; Vol. 30; The Finnish Medical Society Duodecim | |
| | A33 | WILDE, A.A. et al; "Ion channels, the QT interval, and arrhythmias"; Pacing. Clin. Electrophysiol.; 1997; pp 2048-2051; Vol. 20 | |
| | A34 | WISCHMEYER, E. et al; "Subunit interactions in the assembly of neuronal Kir3.0 inwardly rectifying K ⁺ channels"; Mol. Cell. Neurosci.; 1997; pp 194-206; Vol 9; Academic Press | |
| | A35 | YAMADA, M. et al; "G Protein regulation of potassium ion channels"; Pharmacol. Rev.; 1998; pp 723-760; Vol. 50; The American Society for Pharmacology and Experimental Therapeutics, United States | |
| | A36 | BOCK, J.H. et al; "Nucleotide sequence analysis of the human KCNJ1 potassium channel locus"; Gene; 1997; pp 9-16; Vol. 188; Elsevier Science B.V. | |

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



09758036 (SA)
RECEIVED
 JUN 14 2001
 TECH CENTER 1600/2900

Please type a plus sign (+) inside this box → **+**

Approved for use through 10/31/2002 OMB 0651-0031
 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/APTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **4** of **4**

Complete if Known

| | |
|------------------------|------------------|
| Application Number | 09/758,036 |
| Filing Date | January 11, 2001 |
| First Named Inventor | Ekkehard LEBERER |
| Group Art Unit | 1645 |
| Examiner Name | Unassigned |
| Attorney Docket Number | 38005-0126 |

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. 1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T 2 |
|---------------------|------------|---|-----|
| | A37 | DELPON, E. et al; "Blockade of cardiac potassium and other channels by antihistamines"; Drug Safety; 1999; pp 11-18; Vol. 1; Adis International Limited. | |
| | A38 | DRICI, M.D. et al; "Cardiac K ⁺ channels and drug-acquired long QT syndrome" Therapie; 2000; pp 185-193; Vol. 55 | |
| | A39 | DUBUSKE, L.M. "Second-generation antihistamines: the risk of ventricular arrhythmias"; Clin. Ther.; 1999; pp 281-295; Vol. 21 | |
| | A40 | ITO, T. et al; "Genomic organization and mutational analysis of KVLQT1, a gene responsible for familial long QT syndrome"; Hum. Genet.; 1998; pp 290-294; Vol. 103; Springer-Verlag 1998 | |
| | A41 | KOBAYASHI, T. et al; "Inhibition by various antipsychotic drugs of the G-protein-activated inwardly rectifying K(+) (GIRK) channels expressed in xenopus oocytes"; Br. J. Pharmacol; 2000; pp 1716-1722; Vol. 129; Macmillan Publishers Ltd. | |
| | A42 | RICHELSON, E. "Preclinical pharmacology of neuroleptics: focus on new generation compounds"; J. Clin. Psychiatry; 1998; pp 4-11; Vol. 57, Suppl. 11 | |
| | A43 | RICHELSON, E. "Receptor pharmacology of neuroleptics: relation to clinical effects"; J. Clin. Psychiatry; 1999; pp. 5-14; Vol. 60; Suppl. 10 | |
| | A44 | SHUCK, M.E. et al; "Cloning and characterization of multiple forms of the human kidney ROM-K potassium channel"; J. Biol. Chem.; 1994; pp 24261-24270; Vol. 269; The American Society for Biochemistry and Molecular Biology, Inc.; United States | |
| | A45 | TAGLIALATELA, M. et al; "Cardiac ion channels and antihistamines: possible mechanisms of cardiotoxicity"; Clin. Exp. Allergy; 1999; pp 182-189; Vol. 29, Suppl. 3; Blackwell Science Ltd. | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | /Michele K. Joike/ | Date Considered | 07/03/2008 |
|--------------------|--------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.